Technology | February 03, 2012

FDA Clears St. Jude Medical’s Cool Path Duo, Safire BLU Duo Ablation Catheters

February 3, 2012 – The U.S. Food and Drug Administration (FDA) approved the premarket approval application (PMA) for the St. Jude Medical Therapy Cool Path Duo and Satire BLU Duo ablation catheters and the IBI 1500T-9 VI.6 cardiac ablation generator. The system is indicated for creating endocardial lesions during cardiac ablation procedures (mapping, stimulation and ablation) for the treatment of typical atrial flutter.

The cardiac radiofrequency (RF) ablation catheters are compatible with the irrigation pump and 1500T9-CP RF generator at a maximum of 50 watts.

The Therapy Cool Path Duo is a sterile, single use 7 French catheter that is constructed of thermoplastic elastomer material and four noble metal electrodes. This catheter has a through-lumen connected to open conduits at the 4mm tip electrode for heparinized saline irrigation during the ablation procedure. The tip curvature may be manipulated by the thumb control mechanism located on the handle at the proximal end of the catheter. The catheter manipulation is uni-directional. The catheter distal curve is indicated on the catheter label.

The Safire BLU Duo is a sterile, single use 7 French catheter that is constructed of thermoplastic elastomer material and four noble metal electrodes. This catheter has a through-lumen connected to open conduits at the 4 mm tip electrode for heparinized saline irrigation during the ablation procedure. The tip curvature may be manipulated by the thumb and forefinger control mechanism located on the handle at the proximal end of the catheter. The catheter manipulation is bi-directional. The catheter distal curve is indicated on the catheter label.

The catheters are inserted into a blood vessel, usually though a site in the upper leg or neck. The catheter is manually advanced through the blood vessels until it reaches the correct location inside the heart. The tip of the catheter is moved around by a mechanism on the handle. Inside the heart, electrodes at the tip gather data that pinpoint the location of the faulty tissue in the heart (electrical mapping). Once the site is identified, the device delivers RF energy to destroy the small areas of tissue that blocks the heart's internal electrical signals that cause the typical atrial flutter. The catheters are removed after treatment.

In a clinical study involving 188 patients, The FDA said abnormal rhythms (typical atrial flutter) were corrected in 181 patients (96 percent) for seven days after treatment; and it remained corrected after three months in 174 patients (94.5 percent).

For more information: www.fda.gov

 

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Overlay Init